Navigation Links
Micromet Announces Pricing of Public Offering of Common Stock
Date:7/30/2009

BETHESDA, Md., July 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $5.00 per share. All of the shares are being offered by Micromet. The gross proceeds to Micromet, before expenses, from the sale of the shares are expected to be approximately $70 million. The closing of the offering is expected to take place on August 4, 2009. The underwriters have a 30-day option to purchase up to an additional 2,100,000 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. is acting as the sole book running manager with RBC Capital Markets and Merriman Curhan Ford as co-managers in this offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on June 19, 2009 that became effective on July 2, 2009 and a registration statement to be filed with the Securities and Exchange Commission pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet M
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)... -- Research and Markets has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... used to determine the size of a particle in a ... analyze the size of particles as it can affect the ... to determine the behavior and nature of a material, and ...
(Date:7/25/2014)... Trillions of bacteria live in each person,s digestive tract. ... food and stave off harmful infections, but their role ... help shed light on the role of these bacteria, ... Eric Alm recently tracked fluctuations in the bacterial populations ... findings, described in the July 25 issue of the ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... from McGill,s Physics Department and Mike Lilly from Sandia ... electronic circuits. It is formed by two wires separated ... This discovery, published in the journal Nature Nanotechnology ... and power of the ever smaller integrated circuits of ...
... LONDON, December 7, 2011 Silence Therapeutics plc ... ( RNAi ) therapeutics company, announces a positive outcome from the ... (EPO) over opposition to Silence,s granted European Patent EP 1 536 ... The granted patent refers to the gene target PKN3, protein ...
... 2011  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 2.875% Convertible Senior Notes due February 15, 2015 ... $1,000 principal amount or approximately $6.44 per share, effective December ... May 1, 2015 (May 2015 Notes) is 135.9849 shares of ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes 2
(Date:7/27/2014)... study has revealed that nicotine and cotinine, a metabolite ... a certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ... leaves and ultimately ends up in the tobacco smoke. ... liver, where it is activated by a variety of ... has revealed that nicotine can partially interfere with the ...
(Date:7/27/2014)... the southern Western Ghats, a mountain range along the west ... that any mayfly belonging to the genus Labiobaetis ... called Labiobaetis soldani , "is named in honor of ... of the Ephemeroptera of Palaearctic and Oriental realms," according to ... in the Journal of Insect Science . , The ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2New drug target can break down cancer's barrier against treatment 2
... antibacterial medicine that kills the superbug MRSA is being ... Trust. The Seeding Drug Discovery initiative is aimed at ... unmet need. , Prolysis, an R&D company based ... Drug Discovery awards for its new antibacterial compounds aimed ...
... discovery in stem cell research may mean big things for ... a research team at the University of Kentucky published their ... , The researchers genetically mapped a stem cell gene and ... the investigation all the way through to the identification of ...
... as SORL1 may be a factor in the development of ... discovered. The genetic clue, which could lead to a better ... Genetics online, Jan. 14, 2007, and was supported in part ... researchers suggest that faulty versions of the SORL1 gene contribute ...
Cached Biology News:New antibacterials being developed to tackle MRSA superbug 2Researchers first to map gene that regulates adult stem cell growth 2Scientists find new genetic clue to cause of Alzheimer's disease 2
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
... Attoglow Western Blot Analysis Kit is ... kit developed by Biochain. It detects ... g) or yoctomole (10 -24 ... three parts: Millennium Enhancer, protein interaction ...
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... the early 80s Biosearch Technologies has ... oligonucleotide tools to accelerate the discovery ... you need dual-labeled FRET probes and ... oligos for microarray applications, Biosearch can ...
Biology Products: